WO2007147861A3 - Sustained release formulations of aromatase inhibitors - Google Patents

Sustained release formulations of aromatase inhibitors Download PDF

Info

Publication number
WO2007147861A3
WO2007147861A3 PCT/EP2007/056166 EP2007056166W WO2007147861A3 WO 2007147861 A3 WO2007147861 A3 WO 2007147861A3 EP 2007056166 W EP2007056166 W EP 2007056166W WO 2007147861 A3 WO2007147861 A3 WO 2007147861A3
Authority
WO
WIPO (PCT)
Prior art keywords
sustained release
release formulations
aromatase inhibitors
microparticles
discloses
Prior art date
Application number
PCT/EP2007/056166
Other languages
French (fr)
Other versions
WO2007147861A2 (en
Inventor
Oliver Lambert
Marc Riemenschnitter
Vitomire Vucenovic
Original Assignee
Novartis Ag
Oliver Lambert
Marc Riemenschnitter
Vitomire Vucenovic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Oliver Lambert, Marc Riemenschnitter, Vitomire Vucenovic filed Critical Novartis Ag
Priority to EP07765527A priority Critical patent/EP2037884A2/en
Priority to AU2007263004A priority patent/AU2007263004A1/en
Priority to CA002654113A priority patent/CA2654113A1/en
Priority to MX2008015917A priority patent/MX2008015917A/en
Priority to JP2009515878A priority patent/JP2009541264A/en
Publication of WO2007147861A2 publication Critical patent/WO2007147861A2/en
Publication of WO2007147861A3 publication Critical patent/WO2007147861A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses microparticles or nanoparticles comprising an aromatase inhibitor, preferably letrozole, in a polymeric matrix, preferably poly(lactide-co-glycolide) glucose. The invention also discloses sustained release formulations containing said microparticles and the use of said formulations in treating cancer.
PCT/EP2007/056166 2006-06-22 2007-06-20 Sustained release formulations of aromatase inhibitors WO2007147861A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP07765527A EP2037884A2 (en) 2006-06-22 2007-06-20 Sustained release formulations of aromatase inhibitors
AU2007263004A AU2007263004A1 (en) 2006-06-22 2007-06-20 Sustained release formulations of aromatase inhibitors
CA002654113A CA2654113A1 (en) 2006-06-22 2007-06-20 Sustained release formulations of aromatase inhibitors
MX2008015917A MX2008015917A (en) 2006-06-22 2007-06-20 Sustained release formulations of aromatase inhibitors.
JP2009515878A JP2009541264A (en) 2006-06-22 2007-06-20 Sustained release formulation of aromatase inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80550806P 2006-06-22 2006-06-22
US60/805,508 2006-06-22

Publications (2)

Publication Number Publication Date
WO2007147861A2 WO2007147861A2 (en) 2007-12-27
WO2007147861A3 true WO2007147861A3 (en) 2008-02-07

Family

ID=38704831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/056166 WO2007147861A2 (en) 2006-06-22 2007-06-20 Sustained release formulations of aromatase inhibitors

Country Status (9)

Country Link
EP (1) EP2037884A2 (en)
JP (1) JP2009541264A (en)
KR (1) KR20090026345A (en)
CN (1) CN101511341A (en)
AU (1) AU2007263004A1 (en)
CA (1) CA2654113A1 (en)
MX (1) MX2008015917A (en)
RU (1) RU2009101810A (en)
WO (1) WO2007147861A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0914767D0 (en) * 2009-08-24 2009-09-30 Sterix Ltd Compound
WO2012082165A1 (en) * 2010-01-24 2012-06-21 Novartis Ag Irradiated biodegradable polymer microparticles
WO2013063125A1 (en) * 2011-10-24 2013-05-02 Endo Pharmaceuticals Solutions Inc. Implantable drug delivery compositions and methods of treatment thereof
WO2016020901A1 (en) 2014-08-07 2016-02-11 Acerta Pharma B.V. Methods of treating cancers, immune and autoimmune diseases, and inflammatory diseases based on btk occupancy and btk resynthesis rate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030257A2 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles inclusion complexes
WO2007026145A1 (en) * 2005-08-31 2007-03-08 Astrazeneca Ab Prolonged release formulations comprising anastrozole
WO2007026138A1 (en) * 2005-08-31 2007-03-08 Astrazeneca Ab Formulation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030257A2 (en) * 2003-09-30 2005-04-07 Solubest Ltd. Water soluble nanoparticles inclusion complexes
WO2007026145A1 (en) * 2005-08-31 2007-03-08 Astrazeneca Ab Prolonged release formulations comprising anastrozole
WO2007026138A1 (en) * 2005-08-31 2007-03-08 Astrazeneca Ab Formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COOMBES R C ET AL: "AROMATASE INHIBITORS AND THEIR USE IN THE SEQUENTIAL SETTING", ENDOCRINE-RELATED CANCER, JOURNAL OF ENDOCRINOLOGY LTD., BRISTOL, GB, vol. 6, no. 2, June 1999 (1999-06-01), pages 259 - 263, XP000986876, ISSN: 1351-0088 *
INGLE J N ET AL: "Combination hormaonal therapy involving aromatase inhibitors in the management of women with breast cancer", ENDOCRINE-RELATED CANCER, JOURNAL OF ENDOCRINOLOGY LTD., BRISTOL, GB, vol. 6, no. 2, June 1999 (1999-06-01), pages 265 - 269, XP002953773, ISSN: 1351-0088 *

Also Published As

Publication number Publication date
JP2009541264A (en) 2009-11-26
CN101511341A (en) 2009-08-19
RU2009101810A (en) 2010-07-27
CA2654113A1 (en) 2007-12-27
EP2037884A2 (en) 2009-03-25
AU2007263004A1 (en) 2007-12-27
WO2007147861A2 (en) 2007-12-27
MX2008015917A (en) 2009-01-13
KR20090026345A (en) 2009-03-12

Similar Documents

Publication Publication Date Title
WO2007041584A3 (en) Implantable sensors, implantable pumps, and anti-scarring drug combinations
WO2008136519A1 (en) Cytotoxic t cell activator comprising ep4 agonist
WO2007064872A3 (en) Urea compounds useful in the treatment of cancer
WO2008002434A3 (en) Medical devices for release of low solubility therapeutic agents
WO2007089592A3 (en) Implantable medical device coated with bioactive agent
EP1887976A4 (en) Devices, systems and methods for treating benign prostatic hyperplasia and other conditions
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2008060374A3 (en) Methods and compositions useful for diabetic wound healing
WO2008066642A3 (en) Transdermal delivery systems comprising bupivacaine
GB0818178D0 (en) Devices, systems, and methods for medicament delivery
BRPI0810899A2 (en) FORMULATION OF ACTIVATED PLGA NANOParticles loaded with ACTIVE AGENT FOR DIRECTIONAL ANTICANETIC NANO-THERAPEUTIC SUBSTANCES.
WO2007030266A3 (en) Nitric oxide-releasing polymers derived from modified polyimines
WO2008024131A3 (en) Nanoparticle releasing medical devices
WO2008054676A3 (en) Medical devices and methods of using the same
EP1846080A4 (en) Medical agent delivery system and method
WO2007053641A3 (en) A-type procyanidins and inflammation
WO2009025926A3 (en) Nanoparticle-coated medical devices and formulations for treating vascular disease
WO2006093813A3 (en) Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
WO2007095258A3 (en) Rhamnolipid compositions and related methods of use
EP2030615A3 (en) Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
WO2008030427A3 (en) Passive in vivo substance spectroscopy
WO2008010991A3 (en) Methods and compositions for the treatment of cancer
WO2007030611A3 (en) A calculated index of genomic expression of estrogen receptor (er) and er related genes
WO2006138048A3 (en) Formulations comprising fluphenazine or derivatives thereof
WO2010045407A3 (en) Reduction of infection associated with medical device

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780022365.2

Country of ref document: CN

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07765527

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007263004

Country of ref document: AU

Ref document number: 9901/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2007765527

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2654113

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/015917

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009515878

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007263004

Country of ref document: AU

Date of ref document: 20070620

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097001311

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009101810

Country of ref document: RU

Kind code of ref document: A

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0713499

Country of ref document: BR

Kind code of ref document: A2

Free format text: PEDIDO CONSIDERADO RETIRADO EM RELACAO AO BRASIL POR NAO TER CUMPRIDO EXIGENCIA PUBLICADA NA RPI NO 2137 DE 20/12/2011.